Kotchetkov R, et al. - Since rituximab‐related infusion reactions (IRs) represent significant burdens on oncology patients, caregivers and healthcare providers, so, researchers assessed if montelukast and rupatadine enhance rituximab delivery, reduce frequency/severity of IRs as well as the number of medications used to control IRs. They used a nonrandomized clinical study design and evaluated adult rituximab naïve patients suffering from B‐cell lymphoid malignancies. Before the first rituximab infusion, patients were administered one of the premedication regimens: standard premedications, diphenhydramine hydrochloride and acetaminophen (“SP” group); SP + montelukast (“M” group); SP + rupatadine (“R” group); SP + rupatadine + montelukast Schedule 1 (“M + R Schedule 1” group); SP + rupatadine + montelukast Schedule 2 (“M + R Schedule 2” group). The incidence of rituximab IRs was estimated to be 75% in the SP group compared with 44, 41, 22 and 22% in the M, R, M + R Schedule 1 and M + R Schedule 2 groups, respectively. Overall, significant improvement in rituximab delivery, reduction in the rate and severity of IRs as well as decrease in the requirement for rescue medications, was brought about by montelukast and rupatadine.